| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:sepimostate mesilate
CAS:103926-82-5
Purity:95% Package:50mg Remarks:S20508
|
| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:Sepimostat (dimethanesulfonate )
CAS:103926-82-5
Purity:≥98% Package:1g,5g,10g,25g根據(jù)客戶需要分裝 Remarks:Not For Human Use, Lab Use Only.
|
| Company Name: |
Beijing Jin Ming Biotechnology Co., Ltd.
|
| Tel: |
010-60605840 15801484223; |
| Email: |
psaitong@jm-bio.com |
| Products Intro: |
Product Name:Sepimostat dimethanesulfonate
CAS:103926-82-5
Package:5mg;10mg;25mg;50mg;100mg Remarks: 試劑級
|
sepimostate mesilate manufacturers
|
| | sepimostate mesilate Basic information |
| Product Name: | sepimostate mesilate | | Synonyms: | sepimostate mesilate;FUT-187;Sepinostat mesilate;Sepimostat Mesylate;Sepimostat (dimethanesulfonate );6-Carbamimidoylnaphthalen-2-yl 4-((4,5-dihydro-1H-imidazol-2-yl)amino)benzoate dimethanesulfonate | | CAS: | 103926-82-5 | | MF: | C21H19N5O2.2CH4O3S | | MW: | 565.625 | | EINECS: | | | Product Categories: | | | Mol File: | 103926-82-5.mol |  |
| | sepimostate mesilate Chemical Properties |
| Melting point | 248-250° | | storage temp. | Store at -20°C |
| Toxicity | LD50 in male, female mice, male, female rats (mg/kg): 39.4, 41.4, 21.8, 15.8 i.v.; 6284, 5492, 6799, 3343 s.c.; 4395, 3626, 4653, 3761 orally (Terazawa) |
| | sepimostate mesilate Usage And Synthesis |
| Uses | Sepimostat dimethanesulfonate (FUT-187) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat dimethanesulfonate inhibits the Ifenprodil binding with a Ki value of 27.7?μM[1]. | | in vivo | Sepimostat (1 to 100 nmol/eye, intravitreal injection) exhibits significant neuroprotective effect[1]. | Animal Model: | Male Sprague Dawley rats weighing 150-300?g[1]. | | Dosage: | Intravitreal injection. | | Administration: | 1 to 100 nmol/eye. | | Result: | Exhibited neuroprotective effects significantly. |
| | References | [1] Masahiro Fuwa, et al. Nafamostat and Sepimostat Identified as Novel Neuroprotective Agents via NR2B N-methyl-D-aspartate Receptor Antagonism Using a Rat Retinal Excitotoxicity Model. Sci Rep. 2019 Dec 31;9(1):20409. DOI:10.1038/s41598-019-56905-x |
| | sepimostate mesilate Preparation Products And Raw materials |
|